Cromoglicate lisetil

Drug Profile

Cromoglicate lisetil

Alternative Names: Cromoglicate lisetil hydrochloride; Cromoglicic acid; KY-556; LP-0074; N-556

Latest Information Update: 21 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kyoto Pharmaceutical Industries
  • Developer Asahi Kasei; Kyoto Pharmaceutical Industries; LEO Pharma
  • Class Antiallergics; Antiasthmatics; Antihistamines; Benzopyrans; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine release inhibitors; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Mastocytosis; Psoriasis
  • Discontinued Allergic rhinitis; Asthma; Atopic dermatitis

Most Recent Events

  • 21 Jul 2015 No recent reports of development identified - Phase-II for Mastocytosis in Germany (Topical)
  • 21 Jul 2015 No recent reports of development identified - Phase-II for Psoriasis in Germany (Topical)
  • 01 May 2013 LEO Pharma completes a phase II trial in Psoriasis in Germany (NCT01722812)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top